Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Inventory: 2021-2024

Historic Inventory for Apellis Pharmaceuticals (APLS) over the last 4 years, with Dec 2024 value amounting to $81.4 million.

  • Apellis Pharmaceuticals' Inventory rose 1.45% to $122.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.8 million, marking a year-over-year increase of 1.45%. This contributed to the annual value of $81.4 million for FY2024, which is 44.38% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Inventory of $81.4 million as of FY2024, which was down 44.38% from $146.4 million recorded in FY2023.
  • Apellis Pharmaceuticals' 5-year Inventory high stood at $146.4 million for FY2023, and its period low was $16.3 million during FY2021.
  • For the 3-year period, Apellis Pharmaceuticals' Inventory averaged around $104.5 million, with its median value being $85.7 million (2022).
  • Its Inventory has fluctuated over the past 5 years, first surged by 426.30% in 2022, then tumbled by 44.38% in 2024.
  • Over the past 4 years, Apellis Pharmaceuticals' Inventory (Yearly) stood at $16.3 million in 2021, then spiked by 426.30% to $85.7 million in 2022, then soared by 70.76% to $146.4 million in 2023, then slumped by 44.38% to $81.4 million in 2024.